A Randomized, Double-Blind, Vehicle-Controlled, 3-Period, Sequential Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Repeat Topical Applications of GSK2894512 Cream in Healthy Adult Participants
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2018
Price : $35 *
At a glance
- Drugs Tapinarof (Primary)
- Indications Atopic dermatitis; Inflammatory bowel diseases; Plaque psoriasis; Psoriasis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 27 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 05 Sep 2017 Planned End Date changed from 27 Aug 2018 to 15 May 2018.
- 05 Sep 2017 Planned primary completion date changed from 27 Aug 2018 to 15 May 2018.